Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom
Written by Prosper Junior Bakiny for The Motley Fool -> Becton, Dickinson supplies equipment whose demand is soaring due to the rise of GLP-1 medicines. Abbott Laboratories' most important growth dr
Becton, Dickinson supplies equipment whose demand is soaring due to the rise of GLP-1 medicines. Abbott Laboratories' most important growth driver co
Read Full Story at Nasdaq News →Why This Matters
The GLP-1 drug boom isn’t just reshaping healthcare—it’s creating a ripple effect across industries far beyond Big Pharma. Investors who focus solely on Eli Lilly or Novo Nordisk may overlook overlooked beneficiaries whose growth is directly tied to the demand for these weight-loss and diabetes therapies. These two stocks represent a more tactical play, offering exposure to the GLP-1 ecosystem without the volatility of headline-driven biotech bets.
Background Context
The GLP-1 revolution traces its roots to the 2005 FDA approval of Byetta, but it wasn’t until the mid-2010s that the class gained mainstream traction with Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro. Since then, the drugs have evolved from niche treatments for type 2 diabetes to blockbuster weight-loss solutions, with demand outstripping supply and manufacturing bottlenecks becoming a defining challenge. This scarcity has disproportionately benefited suppliers like Becton, Dickinson, whose disposable medical devices and insulin delivery systems are essential to scaling production.
What Happens Next
As GLP-1 drugs become more accessible and new formulations enter the market, the supply chain will face increasing pressure to diversify. Companies with established manufacturing and distribution networks—like Abbott Laboratories—could see sustained growth as they adapt to serve both patients and providers. Meanwhile, smaller players may emerge as acquisition targets if larger firms seek to secure critical supply lines. Watch for earnings reports that reveal whether these suppliers are expanding capacity or hitting capacity ceilings.
Bigger Picture
This is a textbook example of how disruptive therapies can upend entire supply chains, rewarding companies that anticipate rather than react to shifts in demand. The GLP-1 phenomenon underscores a broader trend: in healthcare, the most lucrative investments often lie in the infrastructure that enables innovation, not the innovation itself. As obesity and diabetes rates continue to climb globally, the ripple effects will extend beyond pharma, creating opportunities in medtech, diagnostics, and even consumer health.
